As of November 6, 2026, InflaRx N.V. is a publicly traded company (Nasdaq: IFRX); its largest reported holder is Montanova Capital, LLC, with 15.6% on Schedule 13G/A of August 14, 2026, then Suvretta Capital Management, LLC (11.7%). The largest insider holding is Renfeng Guo, the chief scientific officer and a director, with 1,762,144 shares (2.4% of shares outstanding), per Form 3 of March 18, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in InflaRx N.V.? See the free Snapshot first.
Free to see. No signup.
Is InflaRx N.V. a real, registered company?
- InflaRx N.V. files with the SEC under CIK 1708688 (its SEC filings).
- Its shares are listed under the ticker IFRX on Nasdaq (SEC company record).
- Incorporated in P7; business address in Jena, 2M, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under InflaRx N.V. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Commodore Capital (filed 2026-08-17).
Who are InflaRx N.V.'s owners and officers?
InflaRx N.V.: business address in Jena, 2M; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-17).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-17 | Commodore Capital LP | 5.1% |
| Schedule 13G/A, 2026-08-14 | Montanova Capital, LLC | 15.6% |
| Schedule 13G/A, 2026-08-14 | Farallon Capital Management, L.L.C. | 2.3% |
| Schedule 13G, 2026-08-14 | Sirenia Capital Management LP | 6.1% |
| Schedule 13G, 2026-08-06 | Fmr LLC | 5.5% |
| Schedule 13G, 2026-05-14 | Dapice Joshua J. | 5.1% |
| Schedule 13G, 2026-05-12 | Tcg Crossover Gp Iii, LLC | 9.8% |
| Schedule 13G/A, 2026-02-13 | Suvretta Capital Management, LLC | 11.7% |
Questions about who owns InflaRx N.V.
Who owns InflaRx N.V.?
On this page, 7 holders' latest ownership filings report 5% or more of InflaRx N.V.: Montanova Capital, LLC (15.6%, Schedule 13G/A, filed 2026-08-14), Suvretta Capital Management, LLC (11.7%, Schedule 13G/A, filed 2026-02-13), Tcg Crossover Gp Iii, LLC (9.8%, Schedule 13G, filed 2026-05-12), Sirenia Capital Management LP (6.1%, Schedule 13G, filed 2026-08-14) and Fmr LLC (5.5%, Schedule 13G, filed 2026-08-06); 2 more are listed above.
Who are the largest shareholders of InflaRx N.V.?
By the share each holder's latest filing reports, the largest holders of InflaRx N.V. on this page are Montanova Capital, LLC (15.6%), Suvretta Capital Management, LLC (11.7%) and Tcg Crossover Gp Iii, LLC (9.8%).
When did Montanova Capital, LLC buy into InflaRx N.V.?
The filings give report dates, not purchase dates. The earliest filing from Montanova Capital, LLC on this page is the Schedule 13G/A, filed 2026-08-14, reporting 15.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on InflaRx N.V.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on InflaRx N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InflaRx N.V. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own InflaRx N.V. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief scientific officer and a director: 1,762,144 shares (2.4% of shares outstanding) (Form 3, 2026-03-18).
- , the chief executive and a director: 1,068,908 shares (1.5% of shares outstanding) (Form 3, 2026-03-18).
- , a director: 960,015 shares (1.3% of shares outstanding) (Form 3, 2026-03-18).
- , a director: 490,052 shares (0.68% of shares outstanding) (Form 3, 2026-03-18).
- , a director: 50,000 shares (0.07% of shares outstanding) (Form 3, 2026-03-18).
Shares outstanding: 72,292,859 as of 2025-12-31, from the company's latest SEC cover page.
How much has InflaRx N.V. raised?
No fundraising or offering filing from InflaRx N.V. is on file with us.
Keep reading
More on InflaRx N.V. and the records around it.
InflaRx N.V. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- TCG Crossover GP III, LLC also filed stake reports on 3 other companies: Research Alliance Corporation III (Aug 2026), Entera Bio Ltd. (Aug 2026), Editas Medicine, Inc. (Jun 2026)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), Savara Inc. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), Beta Bionics, Inc. (May 2026), Tyra Biosciences, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/inflarx-nv